ProCE Banner Activity

An Interactive Tool for Managing AEs With Oral Targeted Therapies for HR+, HER2– Breast Cancer

Tool

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with oral targeted therapy for HR-positive, HER2-negative breast cancer from 5 experts.

Released: September 14, 2021

Expiration: September 13, 2022

No longer available for credit.

Share

Faculty

Donna M. Fitzgerald

Donna M. Fitzgerald, PA-C, MPAS

Physician Assistant
Termeer Center for Targeted Therapies
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Matthew P. Goetz

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Marissa Marti-Smith

Marissa Marti-Smith, APRN, AGNP-C, AOCNP

Nurse Practitioner
Breast Oncology
Texas Oncology Baylor Sammons Cancer Center
Dallas, Texas

Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Texas Oncology
Sarah Cannon Research Institute
Dallas, Texas

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner

Additional Information

Program Medium

This program has been made available online.